

C2 9. The method of claim 26 wherein said immunostimulatory dosage increases NK lymphocyte cytotoxicity at least about 50% above the NK lymphocyte cytotoxicity measured prior to administering said dosage.

C3 11. The method of claim 26 wherein said immunostimulatory dosage increases NK lymphocyte cytotoxicity at least about 75% above the NK lymphocyte cytotoxicity measured prior to administering said dosage.

C4 18. The method of claim 26 wherein said non-resectable malignant tumor is selected from the group consisting of breast cancer, lung cancer, pancreatic cancer, brain cancer, prostate cancer, ovarian cancer, uterine cancer, renal cancer, and melanoma.

21. The method of claim 26 wherein said non-resectable malignant tumor is a melanoma.

C5 22. The method of claim 26 wherein said non-resectable malignant tumor is a renal carcinoma.--